Marksans Pharma Inkomsten in het verleden

Verleden criteriumcontroles 1/6

Marksans Pharma is de winst gegroeid met een gemiddeld jaarlijks percentage van 19.7%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 13.3%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 16% per jaar. Het rendement op eigen vermogen van Marksans Pharma is 15.1%, en het heeft een nettomarge van 14.6%.

Belangrijke informatie

19.7%

Groei van de winst

17.4%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	17.5%
Inkomstengroei	16.0%
Rendement op eigen vermogen	15.1%
Nettomarge	14.6%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Jun 07

Recent updates

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Oct 24

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Sep 21

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Jul 28

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Sep 16

Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Sep 01

Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Jun 14

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

May 27

Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Feb 19

Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 04

Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Jan 20

Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Jan 05

Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

Dec 21

What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

Dec 06

Opbrengsten en kosten

Hoe Marksans Pharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NSEI:MARKSANS Opbrengsten, kosten en inkomsten (INR Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven
30 Sep 24	23,787	3,470	3,312
30 Jun 24	22,680	3,338	3,059
31 Mar 24	21,774	3,137	3,059
31 Dec 23	21,034	3,164	2,875
30 Sep 23	19,971	2,965	2,752
30 Jun 23	19,184	2,743	2,637
31 Mar 23	18,521	2,663	2,523
31 Dec 22	17,842	2,123	2,436
30 Sep 22	16,670	2,004	2,375
30 Jun 22	15,756	1,847	2,326
31 Mar 22	14,908	1,868	2,250
31 Dec 21	14,069	2,367	2,351
30 Sep 21	14,026	2,473	2,269
30 Jun 21	14,064	2,518	2,037
31 Mar 21	13,762	2,385	2,096
31 Dec 20	13,817	2,018	1,908
30 Sep 20	13,142	1,724	1,833
30 Jun 20	12,203	1,476	1,700
31 Mar 20	11,344	1,208	1,785
31 Dec 19	10,463	879	1,719
30 Sep 19	9,972	834	1,677
30 Jun 19	10,099	780	1,631
31 Mar 19	10,001	804	1,659
31 Dec 18	9,523	666	1,601
30 Sep 18	9,223	582	1,599
30 Jun 18	9,272	463	1,474
31 Mar 18	9,127	358	1,534
31 Dec 17	8,918	343	1,528
30 Sep 17	8,949	275	1,550
30 Jun 17	8,015	187	1,492
31 Mar 17	7,672	113	1,547
31 Dec 16	7,926	70	1,475
30 Sep 16	7,948	136	1,458
30 Jun 16	8,699	481	1,424
31 Mar 16	8,933	785	1,270
31 Dec 15	8,536	1,093	1,585
30 Sep 15	8,495	1,191	1,397
30 Jun 15	8,045	1,154	728
31 Mar 15	7,967	1,094	758
31 Dec 14	7,850	950	1,482
30 Sep 14	7,405	897	1,121
30 Jun 14	6,914	786	693
31 Mar 14	6,300	719	1,091
31 Dec 13	5,950	1,020	1,013

Kwaliteitswinsten: MARKSANS heeft een hoog niveau van non-cash earnings.

Groeiende winstmarge: De huidige netto winstmarges (14.6%) MARKSANS } zijn lager dan vorig jaar (14.8%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van MARKSANS is de afgelopen 5 jaar met 19.7% per jaar gegroeid.

Versnelling van de groei: De winstgroei van MARKSANS over het afgelopen jaar ( 17% ) ligt onder het 5-jarig gemiddelde ( 19.7% per jaar).

Winst versus industrie: De winstgroei MARKSANS over het afgelopen jaar ( 17% ) overtrof de Pharmaceuticals -sector 20.5%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 15.1% ) van MARKSANS wordt als laag beschouwd.

Marksans Pharma Inkomsten in het verleden

Verleden criteriumcontroles 1/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2025 earnings released: EPS: ₹2.13 (vs ₹1.84 in 2Q 2024)

Marksans Pharma Limited to Report Q2, 2025 Results on Nov 12, 2024

First quarter 2025 earnings released: EPS: ₹1.96 (vs ₹1.52 in 1Q 2024)

Marksans Pharma Limited to Report Q1, 2025 Results on Aug 13, 2024

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Full year 2024 earnings: EPS misses analyst expectations

Recent updates

Price target increased by 26% to ₹330

Second quarter 2025 earnings released: EPS: ₹2.13 (vs ₹1.84 in 2Q 2024)

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Marksans Pharma Limited to Report Q2, 2025 Results on Nov 12, 2024

Marksans Pharma Limited Approves Dividend for the Year Ended March 31, 2024

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Upcoming dividend of ₹0.60 per share

Insufficient new directors

Now 21% overvalued after recent price rise

Successful Closure of US FDA Inspection At Marksans Pharma's Manufacturing Facility Located At Verna, Goa

Investor sentiment improves as stock rises 17%

New minor risk - Share price stability

Marksans Pharma Limited, Annual General Meeting, Sep 24, 2024

First quarter 2025 earnings released: EPS: ₹1.96 (vs ₹1.52 in 1Q 2024)

Marksans Pharma Limited to Report Q1, 2025 Results on Aug 13, 2024

Now 20% overvalued after recent price rise

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Investor sentiment improves as stock rises 18%

Whole-time Director recently bought ₹6.9m worth of stock

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Full year 2024 earnings: EPS misses analyst expectations

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Marksans Pharma Limited Recommends Final Dividend for the Financial Year 2023-24

Marksans Pharma Limited to Report Q4, 2024 Results on May 30, 2024

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 23% overvalued after recent price rise

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Marksans Pharma Limited to Report Q3, 2024 Results on Feb 13, 2024

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: ₹1.84 (vs ₹1.52 in 2Q 2023)

Marksans Pharma Limited to Report Q2, 2024 Results on Nov 09, 2023

Marksans Pharma Limited Appoints Shailaja Vardhan as an Independent Director

Marksans Pharma Ltd. Receives USFDA Approval for Guaifenesin Extended-Release Tablets

Marksans Pharma Limited Recommends Payment of Dividend for the Financial Year 2022-23

Full year 2023 earnings released: EPS: ₹6.39 (vs ₹4.56 in FY 2022)

Marksans Pharma Limited, Annual General Meeting, Aug 28, 2023

Insufficient new directors

Investor sentiment improves as stock rises 16%

Marksans Pharma Limited Announces That It Has Received Final Approval from the Us Food and Drug Administration for Its Abbreviated New Drug Application for Acetaminophen and Ibuprofen Tablets, 250 Mg/125 Mg

Marksans Pharma Limited Approves Declaration of Dividend for the Financial Year 2022-23, Payable on or After 12 June, 2023

Full year 2023 earnings released: EPS: ₹6.41 (vs ₹4.56 in FY 2022)

Marksans Pharma Limited to Report Q4, 2023 Results on May 30, 2023

Third quarter 2023 earnings released: EPS: ₹1.56 (vs ₹1.20 in 3Q 2022)

Marksans Pharma Limited to Report Q3, 2023 Results on Feb 13, 2023

Marksans Pharma Limited announced that it has received funding from OrbiMed Asia IV Mauritius FVCI Limited

Second quarter 2023 earnings released: EPS: ₹1.52 (vs ₹1.11 in 2Q 2022)

Marksans Pharma Limited to Report Q2, 2023 Results on Nov 14, 2022

Marksans Pharma Limited (BSE:524404) entered into a Business Transfer Agreement to acquire Bulk Pharmaceutical Business of Tevapharm India Private Limited.

Marksans Pharma Limited Declares Dividend, Payable on or After 20 September 2022

Upcoming dividend of ₹0.25 per share

Full year 2022 earnings released: EPS: ₹4.56 (vs ₹5.83 in FY 2021)

Marksans Pharma Limited to Report Q1, 2023 Results on Aug 13, 2022

Marksans Pharma Limited, Annual General Meeting, Aug 29, 2022

Marksans Pharma Limited Announces US FDA Approval for Pregabalin Capsules

Marksans Pharma Limited (BSE:524404) announces an Equity Buyback for INR 600 million worth of its shares.

Investor sentiment improved over the past week

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Marksans Pharma Limited (BSE:524404) completed the acquisition of Access Healthcare for Medical Products LLC.

Marksans Pharma Recommends Final Dividend for the Financial Year Ended 31st March, 2022

Marksans Pharma Recommends Final Dividend for the Financial Year Ended 31st March, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Marksans Pharma Limited to Report Fiscal Year 2022 Results on May 30, 2022

Marksans Pharma Limited (BSE:524404) has signed agreement to acquire share capital of Access Healthcare for Medical Products LLC for AED 13 million.

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Marksans Pharma Limited to Report Q3, 2022 Results on Feb 11, 2022

Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)